Conclusion: First line use of SGLT2i and GLP-1RAs is effective in reducing HbA1c, weight, and FPG levels in T2DM patients at low risk for cardiovascular disease
Preparing for your consultation : Before your appointment, document: Your weight history, including previous weight loss attempts and outcomes Current medications and medical conditions Perimenopausal symptoms and their impact on daily life Dietary habits and physical activity levels Family history of obesity, diabetes, or thyroid conditions Specific concerns about weight gain and health goals Questions to discuss with your GP : "Am I eligible for referral to specialist weight management services that might consider GLP-1 medications?" "What are the realistic expectations for weight loss with these treatments?" "How would this medication interact with any HRT or other treatments I'm taking?" "What monitoring would be required during treatment?" "What happens when I stop the medicationwill weight return?" "Are there local NHS weight management services that might help?" "Would addressing my perimenopausal symptoms with HRT potentially help with my overall health?" Setting realistic expectations is crucial
Mogami H, Yura S, Itoh H, Kawamura M, Fujii T, Suzuki A, Aoe S, Ogawa Y, Sagawa N, Konishi I, Fujii S
In our study, lacosamide alone and in cocktails demonstrated a reduction in OS as compared to post-SE control rats and these results are in line with one of the previous study in which lacosamide reversed the elevated MDA and reduced GSH levels in mice, thus reduced OS by its action on the pilocarpine-induced elevated level of CRMP-2 (75)
A spokesperson for the department stated in an email to the Guardian that the state had cut some coverage because of an unsustainable rise in costs from GLP-1s
)
